搜尋
Alterity Therapeutics Ltd
ATHE添加自選
4.415USD
-0.070-1.56%
收盤 07-31 16:00（美東）報價延遲15分鐘
67.16M總市值
虧損本益比TTM
關於 Alterity Therapeutics Ltd 公司
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Alterity Therapeutics Ltd簡介
公司代碼ATHE
公司名稱Alterity Therapeutics Ltd
上市日期Mar 28, 2000
CEOStamler (David A)
員工數量9
證券類型Depository Receipt
年結日Mar 28
公司地址Level 14, 350 Collins Street
城市MELBOURNE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Australia
郵編3000
電話61393494906
網址https://alteritytherapeutics.com/
公司代碼ATHE
上市日期Mar 28, 2000
CEOStamler (David A)
Alterity Therapeutics Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
常見問題
Alterity Therapeutics Ltd的前五大股東是誰？
Alterity Therapeutics Ltd的前五大股東如下：Mr. Peter Ashley Marks
有多少機構持有Alterity Therapeutics Ltd(ATHE)的股份？
截至2026Q1，共有32家機構持有Alterity Therapeutics Ltd的股份，合計持有的股份價值約為327.31K，占公司總股份的1.81% 。與2025Q4相比，機構持股有所增加，增幅為-185355.00。